DULUTH, GA (January 28, 2025) – Boehringer Ingelheim announced today that the U.S. Department of Agriculture (USDA) Center for Veterinary Biologics (CVB) has authorized the importation for emergency use of two of the company’s live virus vaccines produced and registered in the European Union – NEMOVAC® for use in chickens and AVIFFA RTI for use in turkeys – to help protect U.S. poultry against avian metapneumovirus. The vaccines will be available soon in the U.S. 

This announcement follows USDA approval last fall of the importation of the TUR-3 inactivated avian metapneumovirus vaccine produced by Boehringer for use in U.S. turkey and chicken flocks. Avian metapneumovirus is a highly contagious respiratory viral infection that can result in severe respiratory symptoms and increased mortality in poultry as well as a decrease in egg production.  

“Prevention is at the core of poultry health, and our live virus vaccines offer U.S. poultry producers essential tools to help protect their flocks against avian metapneumovirus,” said Steve Boren, head of the Boehringer Ingelheim U.S. Livestock business. “Boehringer Ingelheim is committed to delivering innovation and solutions that safeguard the health and productivity of poultry, contributing to a more secure food supply.” 

“Responding to emerging disease threats like avian metapneumovirus necessitates a collaborative approach between government and industry groups, like the National Turkey Federation, National Chicken Council, and United Egg Producers, and the USDA’s authorization of importation of these vaccines underscores those efforts,” continued Boren. “We look forward to continuing our work with USDA and the poultry industry to combat this ongoing avian metapneumovirus outbreak.” 

Interested parties should contact their Boehringer or distributor representative for additional product information and availability.  

About Boehringer Ingelheim Animal Health  

Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at bi-animalhealth.com.   

About Boehringer Ingelheim  

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Lean more at boehringer-ingelheim.com/us.  

Media Contact
Elizabeth Breeding
Boehringer Ingelheim
Associate Director, PR and Communications
elizabeth.breeding@boehringer-ingelheim.com